Terlipressin-Associated Complete Heart Block

特利加压素相关性完全性房室传导阻滞

阅读:1

Abstract

Terlipressin has been recently approved in the United States to treat hepatorenal syndrome, a feared complication of both acute and chronic liver diseases. Side effects of the medication have been studied through clinical trials and the precedent use in Europe, as well as extrapolation from its analog vasopressin. As its use is becoming more prevalent, unforeseen complications have arisen. We report a case of complete heart block associated with terlipressin use in presumed hepatorenal syndrome in acute liver injury.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。